Cystic endometrial hyperplasia is a sonographic description, not a histological diagnosis. It refers to a thickened, hyperechoic endometrium studded with small anechoic cysts, the so-called Swiss cheese or honeycomb pattern, and in practice you will meet it most often in a postmenopausal woman on tamoxifen. The trap is the word hyperplasia: when these endometria are actually sampled, the commonest findings are endometrial polyps and cystic atrophy, not hyperplasia [1, 2]. This article covers what the pattern means, why endometrial thickness measurement is unreliable in tamoxifen users, and how the April 2026 ACOG update to the postmenopausal-bleeding pathway changes what you should recommend in the report.
Key facts for practice and radiology board exams
- Cystic endometrial hyperplasia is a pattern, not a diagnosis. Histology in tamoxifen-treated women with a thick endometrium is most often polyps or cystic atrophy; frank hyperplasia is uncommon [1, 2].
- The measurement is inflated. Much of the apparent thickening is subendometrial and inner-myometrial cystic change, so the caliper-to-caliper anteroposterior measurement overstates true endometrial thickness [3].
- There is no validated endometrial thickness cut-off in tamoxifen users. The 4 mm postmenopausal-bleeding threshold was never derived in this population and does not transfer.
- Bleeding is the trigger, not the number. Routine surveillance ultrasound of an asymptomatic tamoxifen user is not recommended and generates false positives [4].
- April 2026 changed the pathway. ACOG now recommends transvaginal ultrasonography plus endometrial sampling as the initial evaluation for most patients with postmenopausal bleeding. Ultrasound alone is reserved for a narrow group that excludes anyone with a risk factor such as tamoxifen use [5].
- Saline infusion sonohysterography is the problem-solver. It separates a polyp from diffuse thickening from purely subendometrial cysts, and it found lesions in 63% of women whose blind endometrial biopsy had been reported as normal [6].
- Tamoxifen roughly doubles endometrial cancer risk (pooled RR 2.03), and the risk rises with dose and duration [7]. In the ATLAS trial, extending tamoxifen from 5 to 10 years raised the cumulative endometrial cancer risk over years 5 to 14 from 1.6% to 3.1% [8].
What “cystic endometrial hyperplasia” actually means
The phrase survives from an older histological vocabulary in which “cystic glandular hyperplasia” described dilated, cystically expanded glands. Sonographers borrowed it for the imaging appearance, and it stuck. Two separate things now share the name:
- The sonographic pattern – a thick, echogenic endometrium containing multiple small anechoic spaces. This is what you see and what you should describe.
- The histological entity – endometrial hyperplasia, which since the WHO 2020 classification is a strict two-tier system based on the presence or absence of cytological atypia. This is what the pathologist decides, and imaging cannot predict it.
| WHO 2020 category | Older terms it replaces | Concurrent carcinoma if hysterectomy is done | Risk of progression to carcinoma | Usual management |
|---|---|---|---|---|
| Endometrial hyperplasia without atypia | Simple hyperplasia; complex hyperplasia without atypia | Low | Roughly 1-3% over 20 years | Progestin, commonly a levonorgestrel intrauterine system, with repeat sampling |
| Atypical hyperplasia / endometrial intraepithelial neoplasia (EIN) | Complex atypical hyperplasia; carcinoma in situ | One quarter to one third [9] | Approximately 28% at 20 years | Hysterectomy; progestin therapy if fertility preservation or surgery is not possible [9] |
The practical consequence for the report: describe the pattern, do not label it hyperplasia. “Thickened endometrium with multiple small cystic spaces” is defensible. “Cystic endometrial hyperplasia” asserts a histological diagnosis you cannot make, and in a tamoxifen user it is usually wrong.
Why tamoxifen thickens the endometrium
Tamoxifen is a selective estrogen receptor modulator. It antagonises the estrogen receptor in breast tissue, which is the therapeutic effect, but acts as a partial agonist in the postmenopausal uterus. The result is glandular proliferation together with hypertrophy and oedematous change in the subepithelial stroma, which extends into the inner myometrium. That subendometrial component is why the cysts often appear to straddle the endometrial-myometrial junction rather than sitting neatly inside the endometrial stripe, and it is the anatomical reason the ultrasound measurement is unreliable [3].
Roughly half of women on tamoxifen develop some endometrial abnormality, and both the prevalence and the endometrial thickness increase with duration of therapy [2]. Premenopausal women are affected differently: circulating estrogen dominates, there is no established increase in endometrial cancer risk, and ovarian cysts are the more typical finding [4].
| Finding | How common and why it matters |
|---|---|
| Endometrial polyps | The single most common lesion. Present in 23 of 35 women with a thick endometrium in one hysteroscopy-hysterectomy series [1] and in 62% of sonohysterograms in another [6]. Tamoxifen-related polyps tend to be larger, multiple, and carry a higher rate of harbouring hyperplasia or carcinoma than sporadic polyps [2]. |
| Cystic (glandular) atrophy | The explanation for most apparently thickened endometria that turn out to be benign. Found in 9 of 11 hysterectomy specimens but only 1 of 24 curettage specimens in the same study [1] – blind curettage simply does not retrieve it, so a “normal” biopsy does not exclude it. |
| Endometrial hyperplasia | Less frequent than the sonographic label implies. Only 2 of 5 sonographically thickened endometria were hyperplasia on histology in the Hann series [6]. |
| Endometrial carcinoma | Pooled relative risk 2.03 across 26 studies, increasing with dose and duration [7]. Tamoxifen-related cancers are more often diagnosed at an advanced stage and with unfavourable histology [2]. |
| Uterine sarcoma and carcinosarcoma | Rare, but over-represented in long-term users, and a reason not to dismiss a heterogeneous, vascular endometrial or myometrial mass [2]. |
| Adenomyosis and leiomyomas | Existing lesions may enlarge or become newly conspicuous. Adenomyosis is a classic mimic because the junctional-zone cysts look like the tamoxifen pattern – see our adenomyosis imaging article. |
| Ovarian cysts | Mainly in premenopausal users, from ovarian stimulation. Usually functional and self-limiting; assess with the O-RADS ultrasound calculator if the morphology is not clearly benign. |
Ultrasound findings and the measurement pitfall
Transvaginal ultrasound is the first-line study. Measure in the sagittal plane at the thickest point, anterior to posterior, excluding any intracavitary fluid, following the International Endometrial Tumor Analysis (IETA) conventions [11]. Then read the following table before you commit to a number.
| Feature | Appearance | What can go wrong |
|---|---|---|
| Endometrial thickening | Diffusely thickened, hyperechoic endometrium, often 9-13 mm and sometimes far more | The stripe is measured to the outer echogenic margin, but in tamoxifen users that margin is subendometrial stroma, not endometrium. Reported thickness overstates true endometrial thickness [1, 3]. |
| Cystic spaces (Swiss cheese pattern) | Multiple small anechoic foci within and at the margin of the echogenic stripe | Cysts sitting across the endometrial-myometrial junction are a clue that the process is subendometrial, not endometrial. Sonohysterography settles it [6]. |
| Endometrial polyp | Focal, smoothly marginated, oblong echogenic lesion with a feeding vascular stalk on colour Doppler | A large polyp filling the cavity can be mistaken for diffuse thickening. Scan in the periovulatory phase in premenopausal women, or use sonohysterography. |
| Preserved endometrial-myometrial interface | A smooth, unbroken interface argues against invasion | An irregular or interrupted interface, heterogeneous echotexture and multivessel irregular flow raise concern for carcinoma and mandate sampling regardless of thickness. |
| Colour Doppler | Single feeding vessel favours a polyp; multiple irregular vessels favour malignancy | Doppler refines suspicion but does not exclude cancer, and it never substitutes for tissue. |
MRI is not routine. It is useful when the ultrasound is non-diagnostic or the cavity cannot be assessed. On T2-weighted images the tamoxifen endometrium shows a lattice-like appearance with a heterogeneous, enhancing endometrial and subendometrial layer, and MRI can distinguish an endometrial process from a subendometrial one and help select who needs sampling [3].
What endometrial thickness is abnormal?
This is the question the page originally left unanswered, so here it is directly. The thresholds depend entirely on the clinical scenario, and only one of them is evidence-based.
| Scenario | Threshold | What to do |
|---|---|---|
| Postmenopausal bleeding, no tamoxifen | 4 mm | A fully visualised endometrium of 4 mm or less has a negative predictive value for carcinoma above 99% in classic series [10]. As of April 2026 this alone is no longer sufficient for most patients – see the next section [5]. |
| Postmenopausal bleeding on tamoxifen | No valid threshold | Tamoxifen use is a recognised risk factor for endometrial malignancy. Any bleeding, spotting, staining or bloody discharge requires tissue sampling irrespective of the measurement [4, 5]. |
| Asymptomatic postmenopausal woman on tamoxifen | Not applicable | Do not screen. Routine surveillance ultrasound has not been shown to improve early detection and generates a high false-positive rate driven by cystic atrophy [1, 4]. |
| Asymptomatic postmenopausal woman, incidental thickening, not on tamoxifen | No consensus | Judge on morphology rather than a single number: focality, heterogeneity, an irregular endometrial-myometrial interface and irregular vascularity are what should drive further work-up. |
| Premenopausal woman on tamoxifen | Not applicable | No established increase in endometrial cancer risk. Routine gynaecological care only; investigate heavy or irregular bleeding on its own merits [4]. |
Two caveats worth carrying. First, an individual patient data meta-analysis of 2,896 women found the area under the ROC curve for endometrial thickness to be only 0.82 to 0.84, lower than earlier meta-analyses had suggested, and its authors recommended a 3 mm rather than 4 mm cut-off to exclude carcinoma [12]. Second, threshold performance is not uniform across populations: in a cohort of 1,494 Black patients, 11.4% of endometrial cancers fell below a 5 mm threshold, 9.5% below 4 mm and 3.8% below 3 mm, with a false-negative probability of 26.1% when the endometrium was only partially visualised [13]. Partial visualisation is itself a red flag, not a benign technical note. For other organ-specific normal values, see our normal radiology measurements reference.
The 2026 ACOG update: ultrasound alone is no longer enough
In April 2026 ACOG published a Clinical Practice Update that revises Committee Opinion 734. The headline change is that the combination of transvaginal ultrasonography and endometrial tissue sampling is now recommended as part of the initial evaluation in most patients with postmenopausal bleeding [5]. The rationale is a steadily rising incidence of endometrial cancer, evidence that 5-12% of cancers are missed at initial presentation when ultrasound is used as a triage tool, and the poor performance of thickness thresholds in Black patients [5, 13].
Ultrasound without biopsy remains acceptable only for a selected patient who meets all of the following:
- A single episode of postmenopausal bleeding.
- A sonographically fully visualised endometrium not thicker than 4 mm.
- No factors strongly associated with increased endometrial cancer risk.
- Counselling that continued or recurrent bleeding requires immediate re-evaluation.
- No significant barriers to prompt gynaecological evaluation.
A patient on tamoxifen fails criterion 3. So does a patient whose endometrium you could not fully visualise, which is common in exactly this group because cystic change blurs the margins. In practical terms, for a tamoxifen user with postmenopausal bleeding, the report should recommend tissue sampling regardless of what the calipers said, and should say why.
Distinguishing a polyp from a submucosal fibroid
This distinction matters because a tamoxifen-associated polyp is usually resected, whereas a submucosal fibroid is managed on symptoms. Sonohysterography makes the call in most cases.
| Feature | Endometrial polyp | Submucosal fibroid |
|---|---|---|
| Origin | Endometrium | Myometrium, bulging into the cavity |
| Echogenicity | Iso- to hyperechoic relative to endometrium | Hypoechoic relative to endometrium |
| Attachment | Narrow stalk in most cases, but may be broad-based | Broad base continuous with myometrium |
| Shape | Smoothly marginated, oblong, conforms to the cavity | Round, distorts and indents the cavity |
| Overlying endometrium | Absent – the lesion is endometrium | Intact endometrial layer draped over it |
| Colour Doppler | Single feeding vessel entering through the stalk | Circumferential or peripheral flow |
| Shadowing | None | Edge shadowing or internal attenuation is common |
| On sonohysterography | Echogenic lesion surrounded by fluid, moves with the fluid | Hypoechoic mound covered by endometrium, does not detach from the wall |
When to add sonohysterography
Saline infusion sonohysterography is the single most useful next step when the transvaginal study shows a thick or cystic-appearing endometrium in a tamoxifen user. In 50 sonohysterograms in 48 tamoxifen-treated women it demonstrated 31 polyps (62%), six thickened endometria, five normal endometria and four cases of purely subendometrial cysts. Visualising a normal cavity avoided surgery in 14% of cases. Most striking, among 19 women whose prior blind endometrial biopsy had been reported as normal, 12 (63%) had abnormalities on sonohysterography, including 10 polyps [6].
- Use it to separate a focal lesion from diffuse thickening, confirm that cystic change is subendometrial rather than endometrial, and map a polyp for hysteroscopic resection.
- Do not use it to replace tissue diagnosis in a woman with bleeding. A normal sonohysterogram does not exclude carcinoma.
- Avoid it in active pelvic infection or if pregnancy is possible.
Who needs a biopsy: management by scenario
| Clinical scenario | Recommended action |
|---|---|
| Asymptomatic patient on tamoxifen, thickened or cystic endometrium found incidentally | No further assessment on the basis of imaging alone. Do not schedule surveillance scans [4]. |
| Postmenopausal patient on tamoxifen with any bleeding, spotting, staining or bloody discharge | Transvaginal ultrasound and endometrial sampling. Investigate irrespective of endometrial thickness [4, 5]. |
| Postmenopausal patient not on tamoxifen with a single bleeding episode, fully visualised endometrium 4 mm or less, no risk factors, prompt access to care | Transvaginal ultrasound alone is acceptable, with explicit counselling to return immediately if bleeding recurs [5]. |
| Focal lesion or polyp identified in a tamoxifen user | Hysteroscopic resection rather than blind curettage. Blind sampling misses focal disease [1, 6]. |
| Premenopausal patient on tamoxifen with amenorrhoea or oligomenorrhoea and no risk factors | Expectant management [4]. |
| Premenopausal patient on tamoxifen with heavy or irregular bleeding | Endometrial sampling. |
| Biopsy shows hyperplasia without atypia | Progestin therapy, commonly a levonorgestrel intrauterine system, with repeat sampling. Tamoxifen is usually continued after multidisciplinary discussion with oncology. |
| Biopsy shows atypical hyperplasia / EIN | Hysterectomy is the standard, given that one quarter to one third harbour concurrent carcinoma. Progestin therapy is an option when fertility preservation is required or surgery is not feasible [9]. |
Differential diagnosis of a cystic, thickened endometrium
| Diagnosis | Discriminating features |
|---|---|
| Tamoxifen-related cystic atrophy | Drug history is the whole diagnosis. Cysts straddle the endometrial-myometrial junction; cavity is normal on sonohysterography. |
| Endometrial polyp | Focal, oblong, single feeding vessel. Cystic spaces confined within the lesion. |
| Endometrial hyperplasia | Diffuse, homogeneous thickening; cysts, when present, are small and uniform. Cannot be separated from atrophy by imaging – requires histology. |
| Endometrial carcinoma | Heterogeneous, irregular endometrial-myometrial interface, multivessel irregular flow, often with bleeding. Sample it. |
| Adenomyosis | Junctional zone cysts lie in the myometrium with an indistinct junctional zone, myometrial asymmetry and venetian-blind shadowing. |
| Retained products of conception | Reproductive-age patient with a recent pregnancy event; echogenic material with marked vascularity. See our retained products of conception article. |
| Gestational trophoblastic disease | Raised beta-hCG, a heterogeneous vascular intracavitary mass with multiple cystic spaces. See our early pregnancy ultrasound reference for the early-gestation pitfalls. |
| Endometritis | Thickened endometrium with intracavitary fluid or gas, tenderness and clinical sepsis. |
Reporting checklist
- State the menopausal status, the indication, and whether the patient is on tamoxifen or another SERM. Without the drug history the appearance is uninterpretable.
- Give the endometrial thickness as a sagittal anteroposterior measurement at the thickest point, excluding intracavitary fluid.
- State explicitly whether the endometrium was fully visualised. Partial visualisation materially raises the false-negative rate and removes the patient from the ultrasound-alone pathway [5, 13].
- Describe the pattern rather than labelling it: thickened, heterogeneous, cystic spaces, and whether those cysts appear endometrial or subendometrial.
- Say whether the lesion is focal or diffuse, and report Doppler vascularity – a single feeding vessel versus multiple irregular vessels.
- Comment on the endometrial-myometrial interface and on myometrial and adnexal findings.
- Close with a recommendation that names the pathway: sonohysterography or hysteroscopy for a suspected focal lesion, and tissue sampling for any patient with postmenopausal bleeding on tamoxifen regardless of thickness.
Case walkthrough
Detailed video with PACS-based case images:
Frequently asked questions
References
- McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol. 1998;178(6):1145-1150. PMID: 9662294
- Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94(2):256-266. PMID: 15297160
- Ascher SM, Imaoka I, Lage JM. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology. 2000;214(1):29-38. PMID: 10644098
- Committee on Gynecologic Practice. Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123(6):1394-1397. PMID: 24848920
- American College of Obstetricians and Gynecologists. Updated guidance regarding the role of transvaginal ultrasonography in evaluating the endometrium of individuals with postmenopausal bleeding. Obstet Gynecol. 2026;148(1):e87-e91. PMID: 41990335
- Hann LE, Gretz EM, Bach AM, Francis SM. Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. AJR Am J Roentgenol. 2001;177(2):337-342. PMID: 11461858
- Ghanavati M, Khorshidi Y, Shadnoush M, Akbari ME, Ardehali SH, Chavarri-Guerra Y, et al. Tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose-response meta-analysis. Cancer Rep (Hoboken). 2023;6(4):e1806. PMID: 36916539
- Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816. PMID: 23219286
- American College of Obstetricians and Gynecologists. Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol. 2023;142(3):735-744. PMID: 37590985
- Goldstein RB, Bree RL, Benson CB, Benacerraf BR, Bloss JD, Carlos R, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-sponsored consensus conference statement. J Ultrasound Med. 2001;20(10):1025-1036. PMID: 11587008
- Leone FP, Timmerman D, Bourne T, Valentin L, Epstein E, Goldstein SR, et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet Gynecol. 2010;35(1):103-112. PMID: 20014360
- Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):160-167. PMID: 20567183
- Doll KM, Pike M, Alson J, Williams P, Carey E, Sturmer T, et al. Endometrial thickness as diagnostic triage for endometrial cancer among Black individuals. JAMA Oncol. 2024;10(8):1068-1076. PMID: 38935372
For more genitourinary radiology cases, see the RadioGyan case library, or watch the playlist below.
Improve Content And Help Your Colleagues!
Found an error in the post? Please let us know using our contact page and we will update it with due credits!
If you wish to contribute radiological images for this case (or any other article on the website), you can submit them here and you will be duly credited: Submit radiology case